Can Eli Lilly Stock Keep Surging As Drug Prices Fall?

The past year’s gain was bought with volume and access, and management has already said net price goes lower from here.

Eli Lilly (LLY) stock returned 78.5% over the past twelve months, against 20.2% for the S&P 500. Eli Lilly outpaced most large-cap pharma peers over the same stretch—beating Johnson & Johnson (57.7%) and Pfizer (21.6%)—though Merck delivered a higher gain still, at 89.5%. What actually drove that gain sits one layer down, in units rather than price: Lilly opened one door after another to people who could not previously get the medicines.

Units Carried Every Dollar Of Domestic Growth

In Q2 2026, U.S. revenue grew 33% while U.S. price declined 3% – a decline of 9% once a change to estimates for rebates and discounts is stripped out. Revenue rising by a third with the price line falling is a pure volume result. Mounjaro and Zepbound alone produced $14.9 billion of worldwide revenue in Q2 2026 and $6.3 billion of the growth over Q2 2025, nearly all of the almost $6.8 billion that Lilly’s whole Key Products group added in the same comparison. Companywide revenue over the past twelve months reached $79.7 billion, up 49.6%, faster than the 39.4% the company averaged over the prior three years.

Wider Access Will Cost It Price, Management Says

The volume strategy is about to accelerate. The Medicare GLP-1 Bridge program launched on July 1 at an out-of-pocket price of $50 per month, granting 20 million eligible Americans insurance coverage for GLP-1s for obesity, an expansion management says leaves 35% more people in the United States with coverage for its obesity medicines. Mounjaro is now reimbursed for both type 2 diabetes and obesity in France. Broader access through CVS starts in the fourth quarter of 2026, and the finance chief has said plainly that net price will go down because of that access, and that volume growth will more than offset the decline.

Trading price for access usually costs margin, and Lilly enters the trade from a position of strength: operating margin over the past twelve months is 49.7%, against a three-year average of 39.0%. That twelve-month window almost entirely predates the access it is about to give, so it is a starting point, not a verdict. Growth that arrives with margin behind it is the property the Trefis High Quality Portfolio looks for in its holdings.

Volume Will Have To Outrun A Falling Price Line

The real test of trading price for access is still ahead, because the CVS change has not yet landed. Lilly has raised the low end of its full-year 2026 revenue range by $3 billion and the high end by $2 billion, so the guide has moved up. The doubt sits with Foundayo, the oral GLP-1, whose U.S. launch curve has been called slower than anticipated; the counter is distribution, with prescribers up from the 8,000 named on the prior earnings call to 36,000 on the Q2 2026 call. So the units are what to track from here: as long as prescriptions arrive faster than net price falls, the guide can rise again, and companies whose guidance is still moving up are the group to check Lilly against.

Growth This Fast Still Sits In One Franchise

Lilly’s growth is running on one franchise, and an investor who owns only Lilly inherits every wobble that franchise has. The Trefis High Quality Portfolio is the other way to hold quality, a rules-based basket rather than a single bet. That portfolio has a track record of outpacing the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.